Regulators in Europe have given the green light to GlaxoSmithKline’s new chronic obstructive pulmonary disease drug Incruse.
Specifically, the European Commission has granted marketing authorisation for Incruse (umeclidinium) as a once-daily treatment to relieve symptoms in adults with COPD. The drug is a once-daily long-acting muscarinic antagonist (LAMA) delivered by GSK’s Ellipta inhaler.
Read more at: http://www.pharmatimes.com/Article/14-04-28/Europe_green_light_for_GSK_COPD_drug.aspx#ixzz30Lohff26
Follow us: @PharmaTimes on Twitter
read
http://www.pharmatimes.com/Article/14-04-28/Europe_green_light_for_GSK_COPD_drug.aspx
